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Abstract
Background: The objective of our study was to investigate the clinical characteristics and prognosis of postterm
choriocarcinoma patients at Peking Union Medical College Hospital within the past 30 years.
Methods: The clinical characteristics and pertinent follow-up data of 272 patients with postterm choriocarcinoma
diagnosed from December 1985 through December 2014 in our hospital were reviewed. The clinical characteristics
of two cohorts cut off at 2006 were compared using χ2 tests. Risk factors of prognosis were estimated by multivariate
Cox proportional regression analysis.
Results: The most common initial symptom was abnormal uterine bleeding. After individualized treatment 239
patients (87.9 %) achieved complete remission, including 140 patients received initial treatment of 5-fluorouracil-based
multidrug chemotherapy. There were almost no statistically significant differences in the clinical characteristics and
survival rates between the two cohorts. The results of the multivariate analysis showed that history of resistance to
multidrug chemotherapy, liver metastasis and FIGO score greater than 12 were independent risk factors of prognosis.
Conclusions: Postterm choriocarcinoma patients were usually accompanied by several high-risk factors that should
received combined chemotherapy to prevent delay in adequate treatment. 5-fluorouracil-based multidrug
chemotherapy, which has been applied at PUMCH for several decades, can be an effective initial treatment
for postterm choriocarcinoma patients. More emphasis should be placed on those who have history of
resistance to multidrug chemotherapy, liver metastasis or a FIGO score greater than 12.
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Background
Gestational trophoblastic neoplasia (GTN) is consid-
ered to be one of the most curable human malignan-
cies. Due to the precise measurement of human
chorionic gonadotropin (hCG) levels, effective com-
bination chemotherapy and other viable procedures
such as surgeries, the cure rate can reach 90 % even
for widespread metastases [1].
Choriocarcinoma, a type of gestational trophoblastic
neoplasia, can follow any form of pregnancy, such as
hydatidiform moles, abortion, term pregnancy or ectopic
gestation [2]. Among these, the incidence of postterm
choriocarcinoma has been reported to be as low as ap-
proximately 1 in 50,000 births [3]. Limited information
is available about this specific form of choriocarcinoma
due to its rarity. However several studies have identified
that an antecedent term pregnancy could be an import-
ant risk factor of prognosis [4, 5]. Our previous study on
cases between December 1985 to December 2006 also
indicated that 108 patients (108/123 87.8 %) achieved
complete remission (CR) and patients who had an inter-
val between pregnancy and diagnosis greater than
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12 months were more inclined toward an adverse prog-
nosis than patients in other subgroups [6].
The objective of our present study was to investi-
gate the clinical characteristics and prognosis of pa-
tients with postterm choriocarcinoma by surveying
the cases treated at Peking Union Medical College
Hospital (PUMCH) over the previous 30 years as well
as compare the new data with our prior study to see
if there were any differences in clinical characteristics.
Furthermore, this paper gives a view of prognosis-
related factors through the analysis of almost 270
cases for the first time.
Methods
Patients
From December 1985 through December 2014, 1418 pa-
tients with choriocarcinoma were admitted to PUMCH.
Of these patients, 272 had an antecedent gestation of
term pregnancy, including a new series of 149 cases
from January 2007 through December 2014, which made
the total prevalence rate 19.2 %. This study was ap-
proved by the ethics committee of Peking Union Med-
ical College Hospital. The informed consent was waived
because the study was retrospective in design and from
public data-sets.
The age ranged from 21 to 57 years old (mean
31 years) with 24 (8.8 %) patients older than 40. 111
(40.8 %) patients in the cohort had an interval of more
than 12 months from the index pregnancy. The Inter-
national Federation of Gynecology and Obstetrics
(FIGO) score ranged from 2 to 20 (mean 9). 87 (40.0 %)
were low-risk patients and 185 were high-risk patients
according to the new FIGO prognosis scoring system.
Forty-six patients were diagnosed as stage I, 9 with stage
II, 161 with stage III, and 56 with stage IV. The mean β-
hCG levels before treatment in our hospital was 110,852
(range negative-3120000) mIU/ml. The percentage of
patients with metastatic disease was 83.1 % (226/272).
Seventy-seven patients with no less than two metastatic
sites accounted for 34.1 % of the metastatic patients,
which includes 22 cases of vaginal metastases, 6 ovary
metastases, 77 lung metastases, 41 brain metastases, 10
liver metastases, 6 kidney metastases, 3 spleen metasta-
ses, 4 adrenal gland metastases, 4 gastrointestinal tract
metastases and other distant metastases. Fifty-nine pa-
tients had two metastatic sites, 11 patients had three
sites of metastases and the other 7 had four metastatic
sites. One of the most common symptoms of postterm
choriocarcinoma was abnormal uterine bleeding, which
occurred in 202 (74.3 %) patients. The other symptoms
included hemoptysis and central neural system symp-
toms (e.g., headache). The comparisons of clinical char-
acteristics of the prior and new case series are displayed
in Table 1.
Treatment
All of the patients underwent a systematic evaluation
including a review of medical history; physical examin-
ation; testing of complete blood count, serum biochem-
istry, liver and renal function, and serum β-hCG levels;
and scanning by chest computed tomography (CT),
pelvic and abdominal ultrasound or magnetic resonance
imaging (MRI) and either brain CT or MRI when
patients complained of neurological symptoms before
receiving treatment in our hospital.
The standard treatments for patients with postterm
choriocarcinoma were chemotherapy and sometimes
surgery when the lesions appeared to be localized and
resistant to chemotherapy. The chemotherapy agents
used for the new and old cohort were similar. Chemo-
therapies utilizing 5-fluorouracil such as FAEV (5-fluo-
rouracil/FUDR, actinomycin-D, vincristine, etoposide)
and FAV (5-fluorouracil/FUDR, actinomycin-D, vincris-
tine) were used as the first-line treatment in our hospital
for untreated patients and patients who showed resist-
ance to previously applied protocols that didn’t included
5-fluorouracil/FUDR. While the others transferred from
other hospitals received multiple regimens as their first
line chemotherapy agents. The details of FAEV or FAV
protocol were as follows: vincristine 2 mg administered by
bolus intravenously 3 h before actinomycin-D on day 1;
actinomycin-D 200 μg/m2 administered by infusion more
than 30 min daily on days 1–5; FUDR 800 mg/m2 admin-
istered by infusion more than 8 h daily on days 1–5; with
or without etoposide 100 mg/m2 administered by infusion
more than 30 min daily on days 1–5. The protocol was
administered every 21 days. Patients discontinued the
treatment if they had two or three additional courses
of consolidation chemotherapy. The salvage chemo-
therapies included EMA/CO (etoposide, methotrexate,
actinomycin-D/cyclophosphamide, vincristine), EMA/
EP (etoposide, methotrexate, actinomycin-D/etoposide,
cisplatin), TE/TP (paclitaxel, etoposide/paclitaxel, cis-
platin) and other cisplatin-based chemotherapies. The
toxicity of chemotherapy was evaluated for every cycle
according to the WHO criteria. The hematologic toxicity,
gastrointestinal reaction and alopecia were the most com-
mon side effects of the FAV/FAEV protocols. The occur-
rence rate of grade III ~ IV side effects, as much as 19.7 %
(426/2163), were comparable to other multi-agents che-
motherapies [1].
The mean courses of chemotherapy was 8 (1–27). One
hundred twenty-one patients developed resistance to
multiagent chemotherapies before they were admitted to
our hospital, and 33 of these had previously received an
EMA/CO regimen. The other 151 patients received
either primary FAV or FAEV combination chemotherapy
in our hospital. Within the whole cohort, 141 patients
underwent 163 surgeries, including hysterectomy with
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or without bilateral salpingectomy and other surgeries to
remove the chemoresistant metastatic lesions or in case
of emergency. Forty-one patients with brain metastases
received systematic chemotherapy and intrathecal injec-
tion of methotrexate (MTX).
Efficacy assessment
Complete remission (CR) was defined as consecutively
normal serum β-hCG levels for at least 4 weeks. Partial
remission (PR) refers to conditions in which either
lesions were reduced by 50 % or the serum β-hCG titers
decreased by more than 50 %. Progression of disease
(PD) was diagnosed when there were either consistent
or rising serum β-hCG levels or new metastases. When
β-hCG titers did not decline logarithmically or new
metastases appeared after two or three cycles of chemo-
therapy, chemoresistance was diagnosed, and the patient
was switched to salvage regimens.
Statistical analysis
Results were presented as either the mean (SD) or
median (range) and analyzed with the Statistical Pack-
age for the Social Science (SPSS 17.0, Armonk, NY,
USA). The comparison of the mean between the case
series was performed using t-tests. Ratios were com-
pared using the chi-square test. The survival time was
defined as the period between diagnosis and last
follow-up or death. Loss of follow-up was considered
to be censored data. The overall survival was analyzed
by a Kaplan-Meier curve. Univariate analysis of the
log rank test was used to estimate the influence of
single factor on the overall survival, whereas the
multivariate Cox proportional regression analysis was
performed to determine the combination of factors
that were statistically significant in the univariate ana-
lysis. The level of statistical significance was defined
as P < 0.05.
Table 1 Comparisons of clinical characteristics
1985–2006 2007–2014 P value
N = 123 N = 149
Mean age 30(22–57) 31(21–54) 0.25
Median gravidity 2(1–10) 2(1–8) 0.17
Median parity 1(1–9) 1(1–4) 0.56
Previous hydatidiform mole or invasive mole 21(17 %) 27(18 %) 0.82
Median interval from index pregnancy, months 7(0–216) 13(0–348) 0.002
Interval from index pregnancy <4 mo 47(38 %) 31(21 %) 0.002
Interval from index pregnancy >12 mo 36(29 %) 75(50 %) 0.000
Mean pretreatment β-hCG mIU/ml 119692 (6.5-3120000) 103554 (negative-2876010) 0.67
Pretreatment >400,000 β-hCG mIU/ml 5(4 %) 10(7 %) 0.34
Metastatic disease 98(80 %) 128(86 %) 0.17
Metastatic sites ≥2 38(31 %) 39(26 %) 0.39
Symptoms
Abnormal uterine bleeding 91(74 %) 111(74 %) 0.92
Hemoptysis 14(11 %) 13(9 %) 0.47
Central neural system symptoms 12(10 %) 4(3 %) 0.17
Fetal death or stillbirth 3(2 %) 11(7 %) 0.07
Resistance to multiagent chemotherapy 49(40 %) 72(48 %) 0.16
Mean chemotherapy courses 8.5(1–27) 7.5(1–26) 0.44
Numbers of surgeries 75(61 %) 88(59 %) 0.75
Mean FIGO score 9.2(2–19) 9.4(2–22) 0.59
FIGO score >12 25(20 %) 31(21 %) 0.92
FIGO stage
I 24(20 %) 22(15 %) 0.30
II 9(7 %) 0(0 %) n/aa
III 66(54 %) 95(64 %) 0.09
IV 24(19 %) 32(21 %) 0.69
a chi-square test undefined
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Results
Prognosis
After systematic chemotherapies and certain individual-
ized treatments, 239 (87.9 %) of the patients achieved
CR, 8 achieved PR and the remaining 25 showed disease
progression. Of the 151 patients who received either pri-
mary FAV or FAEV combination chemotherapy in our
hospital, 140 (92.7 %) patients achieved CR. The CR rate
of other patients who had a history of failed multidrug
chemotherapy was only 81.8 % (99/121). The compari-
son of CR rate of our 272 post-term choriocarcinoma
patients with CR rate of other patients treated for all
gestational trophoblastic neoplasia at PUMCH for stage
is shown in Table 2.
Twenty-two patients died after receiving the initial
treatment, 11 of whom (50 %) died of multiple organ
failure due to the spread of the disease. Five of the
patients had a cerebral hernia, and two had heart failure
or renal failure due to heart and kidney metastases,
respectively. 6 patients died of infectious shock, pneu-
morrhagia and respiratory failure caused by severe bone
marrow suppression after chemotherapy. All of the
surviving patients underwent follow-up either at out-
patient clinics or through telephone interviews, except
for 13 cases that were lost to follow up; the median
follow-up time was 21 months (range 5–102 months).
Seventeen cases relapsed within 3–24 months after
initial remission, which included 3 cases of two-time
relapses and one patient who relapsed three times.
Fifteen of the relapses occurred within 6 months of re-
mission and 3 patients died of disease progression. In
total, 25 patients died of the disease, which made the
overall 5-year survival rate 86.7 % (Fig. 1a).
Comparisons of prior and new cohort
There were no statistically significant differences in the
majority of the clinical characteristics between the two
cohorts as displayed in Table 1. But the interval between
the antecedent pregnancy and diagnosis appeared to be
longer in the new cohort, extending from less than
1 month to 29 years (median 13 months) in the new co-
hort compared to the prior (P = 0.002, older series
median interval 7 months). Nearly half of the patients in
the new cohort had an interval of more than 12 months
from the index pregnancy (P < 0.01). There was no sig-
nificant difference between the prior and new cohorts
with regard to the CR rate and survival rate (87.8 % vs.
87.9 %, 86.8 % vs. 87.3 %, respectively; P = 0.98, P = 0.61)
either (Fig. 1b).
Prognosis-related risk factors
The univariate analysis of prognosis-related factors on
postterm choriocarcinoma patients is illustrated in
Table 3. The interval from index pregnancy, the number
of metastatic sites, a history of resistance to multiagent
chemotherapy, liver metastasis and the FIGO score were
related to the prognosis. All of the aforementioned
factors were brought into the multivariate analysis.
According to the results in Table 4, a history of re-
sistance to multiagent chemotherapy [Relative Risk
(RR) 2.613, 95 % CI 1.074–6.358, P = 0.034], liver me-
tastasis (RR 5.393, 95 % CI 1.932–15.06, P = 0.001)
and a FIGO score greater than 12 (RR 3.691, 95 % CI
1.660–8.205, P = 0.001) were independent risk factors
for patient prognosis.
Discussion
Postterm choriocarcinoma had seldom been reported
because of its low incidence. Publications available are
mostly case reports and occasionally case series of
dozens of patients [6–10]. We conducted a retrospective
study of 272 patients with regard to the risk factors that
might be related to patient prognosis and compared a
new cohort of 149 cases with that of a previously pub-
lished series. Based on our observations, we concluded
that the clinical characteristics of postterm choriocarcin-
oma in recent years had no obvious changes except for a
later interval to diagnosis and delayed transferring to
our hospital. The complete remission rate and 5-year
overall survival rate of postterm choriocarcinoma pa-
tients in our cohorts were 87.9 and 86.7 %, respectively.
A history of resistance to multiagent chemotherapy, liver
metastasis and a FIGO score greater than 12 were
shown to be independent risk factors of prognosis. To
Table 2 Comparison of CR rate of 272 post-term choriocarcinoma with CR rate of other gestational trophoblastic neoplasia at
PUMCH for stage
Postterm choriocarcinoma Other gestational trophoblstic neoplasia P value
No. of CR CR rate No. of CR CR rate
FIGO stage 239 87.9 % 2162 92.5 % 0.008
I 45 97.8 % 818 99.5 % 0.141
II 9 100 % 125 93.3 % n/aa
III 145 90.1 % 1095 89.4 % 0.793
IV 40 71.4 % 124 79.0 % 0.249
a chi-square test undefined
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the best of our knowledge, we consider the sample size
of this research to be the largest studied, and this is the
first instance of applying multivariate analysis of risk fac-
tors for prognosis in postterm choriocarcinoma patients.
Most of the clinical characteristics of patients in our
cohort were similar to other studies [7–10]. The most
common symptom reported is abnormal uterine bleed-
ing. Ryu et al. separated 24 patients into two groups ac-
cording to their interval from the index pregnancy. The
results showed that regardless of the time between the
prior and current gestations, the most common initial
symptom of postterm choriocarcinoma is irregular vagi-
nal bleeding [8]. Ryu et al. also observed that persistent
vaginal bleeding during pregnancy could be a sign of dis-
ease and required careful pathologic examination of the
placenta to acquire an early diagnosis. Odunsi et al. re-
ported a case of one patient who had secondary postpar-
tum hemorrhaging and an anemic neonate, which was
diagnosed as choriocarcinoma [11]. We considered a
routine β -hCG test valuable for patients with abnormal
vaginal bleeding either postpartum or during the preg-
nancy to exclude choriocarcinoma.
The median interval from the index pregnancy to time
of diagnosis was 13 months in our new cohort. There
was a statistically significant increase in the interval
from index pregnancy (P = 0.002), as has also been previ-
ously reported [10]; however, the prognosis was un-
changed. The longer intervals were perhaps due to
delayed referrals to our hospital, which is considered
to be a referral center for gestational trophoblastic
Fig. 1 Kaplan-Meier curve for overall survival of a 272 postterm choriocarcinoma patients; b prior and new cohort respectively
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disease that usually admits chemoresistant cases.
Diver et al. observed more patients with fewer symp-
toms in a new series of patients who were diagnosed
with choriocarcinoma, which could result in a delayed
diagnosis [10]. Their study indicated that a timely
diagnosis in postterm choriocarcinoma patients was
required.
Almost all of the untreated patients in the new cohort
received combined chemotherapies as their initial treat-
ment. We conducted a comparison of CR rate of post-
term choriocarcinoma patients with other patients
treated for gestational trophoblastic neoplasia at the
PUMCH for stage (Table 2). The results showed that
there were no statistically significant difference when the
CR rate was compared according to the stage subgroup.
What’s more, the percentage of stage IV patients in post-
term choriocarcinoma was higher than that in other
patients treated for gestational trophoblastic neoplasia
(20.7 % vs 6.7 %, P < 0.001). It appeared that stage might
be a confounder of the association between postterm
choriocarcinoma and relatively adverse prognosis. In
other words, postterm choriocarcinoma was probably
not a high-risk factor itself. These patients were possibly
at higher risk because of other associated factors such as
anatomical stage. Nevertheless, Lok et al. reported that
choriocarcinoma following a term pregnancy was con-
sidered to be an independent high risk factor in the
Netherlands because the high-risk status of postterm
choriocarcinoma couldn’t be totally revealed by one or
two traditional high-risk factors. Meanwhile, no sub-
group could be identified in which single-agent chemo-
therapy would be used as initial treatment safely [7].
Lybol et al. conducted a retrospective study of the fatal
cases of gestational trophoblastic neoplasia and found
that 19 of 26 (73.1 %) cases were following a term preg-
nancy, and most of these deaths were due to a metastatic
tumor. They suggested that gestational trophoblastic
neoplasia following term pregnancy should be considered
a high-risk disease, which probably contributed to a de-
cline in fatal cases [5]. In our opinion, term pregnancy
accounted for two points in the FIGO prognosis scoring
system regardless of other risk factors. Whether term
pregnancy is a high-risk factor itself or because of other
associated factors still need more researches. But what’s
more important is that the patients of postterm choriocar-
cinoma were usually accompanied by several high-risk
factors that should received combined chemotherapy to
prevent delay in adequate treatment. Chemotherapies
containing 5-fluorouracil such as FAEV or FAV have been
used in our hospital for several decades [12–14]. Almost
all of the untreated patients and patients who exhibited
resistance to protocols that lacked 5-fluorouracil/FUDR
received either FAEV or FAV as their initial treatment.
The study in the United States [10] also showed that the
Table 3 The univariate analysis of prognosis related factors on
272 postterm choriocarcinoma patients




<40 (n = 250) 88.0
≥40 (n = 22) 72.7 0.13
Medical history of molar gestation
Yes (n = 48) 84.3
No (n = 224) 87.1 0.70
Interval from index pregnancy,month
≤12 (n = 161) 93.2
>12 (n = 111) 79.0 0.01
Pretreatment β-hCG,mIU/ml
<100,000 (n = 220) 84.9
≥ 100,000 (n = 52) 94.0 0.34
<400,000 (n = 257) 86.3
≥ 400,000 (n = 15) 93.3 0.79
Metastatic sites
1 (n = 195) 91.0
≥2 (n = 77) 75.9 0.004
Abnormal uterine bleeding only
Yes (n = 139) 88.4
No (n = 133) 82.8 0.344
Fetal death or stillbirth
Yes (n = 14) 92.9
No (n = 258) 86.2 0.66
Resistance to multiagent chemotherapy
Yes (n = 121) 76.3
No (n = 151) 95.3 0.004
Brain metastasis
Yes (n = 41) 80.6
No (n = 231) 87.9 0.13
Kidney metastasis
Yes (n = 6) 83.3
No (n = 266) 86.7 0.55
Liver metastasis
Yes (n = 10) 33.3
No (n = 262) 89.0 0.000
Surgeries
Yes (n = 141) 85.5
No (n = 131) 87.4 0.25
FIGO score
≤12 (n = 216) 90.9
>12 (n = 56) 71.3 0.000
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patients who underwent single-agent chemotherapy at
first required altered combination chemotherapy to
achieve remission.
Though the previous gestation of term pregnancy was
considered a risk factor for prognosis in choriocarcin-
oma patients, the recently reported complete remission
rate was approximately 86 % worldwide [7, 10]. Our data
showed that the CR rate of 272 cases was 87.9% and
both FAEV and FAV were effective combined chemo-
therapies when treating postterm choriocarcinoma pa-
tients in China and could be an alternative option for
the initial chemotherapy. Twenty-five patients died from
the disease during the treatment and follow-up period;
18 (84.0 %) of these patients died from either metastatic
disease and or treatment-related issues. The overall 5-
year survival rate of postterm choriocarcinoma patients
was first reported as 86.7 % in this study, and there have
been no improvements in the prognosis over the past
10 years. Another report revealed the same trend and
speculated that the prognosis using more recent data
could be better because of the initial combined chemo-
therapies, including EMA/CO [10].
The prognosis analysis in our prior study showed that
an interval from the index pregnancy to diagnosis longer
than 12 months, pretreatment β-hCG levels greater than
100,000 IU/L, FIGO stage IV and high-risk disease were
related to an adverse prognosis [6]. Other literature also
illustrated that a FIGO score greater than 8, multiple
metastases, higher FIGO stages and pretreatment β-hCG
levels greater than 40,000 IU/L were risk factors for a
poor prognosis [15]. The present study discovered that
the interval from index pregnancy to time of diagnosis,
the number of metastatic sites, a history of resistance to
multiagent chemotherapy, liver metastasis and FIGO
score were related to the prognosis. The relationship
between presenting symptoms and prognosis shown
in Table 3 illustrated that the abnormal uterine bleed-
ing alone had no significant effect on prognosis.
However, Olive et al. found that presenting symptom-
atology other than abnormal uterine bleeding signifi-
cantly decreased response to treatment in patients
with postterm choriocarcinoma [16]. The presenting
symptom could be the indication of tumor burden
which was usually revealed by the serum β-hCG
levels. According to our results, β-hCG levels had no
significant effect on prognosis, either. Whether the
presenting symptom was a significant prognostic fac-
tor or not still remains a question. After multivariate
analysis, a history of resistance to multiagent chemo-
therapy, liver metastasis and a FIGO score greater
than 12 were independent risk factors of the prognosis.
Although the number of metastatic sites was significant
only in the univariate analysis, we still considered it an im-
portant factor related to patient prognosis. After analyzing
the data of patients metastases ≥2 sites, we found that
nearly 80 % (60/77) of them had the history of resistance
to multiagent chemotherapy. The effect of metastases ≥ 2
sites on prognosis might be explained by the factor of re-
sistance to multiagent chemotherapy. On the other hand,
there were only a few patients with more than two meta-
static sites. More cases with more than two metastatic
sites are necessary to determine whether the number of
metastatic sites (e.g., >2) is related to the prognosis. Kid-
ney metastasis concomitant with other distant metastases
was considered a risk factor in some reports [13, 14]. Be-
cause of the small sample size, the survival rate of patients
with or without kidney metastasis had no statistically sig-
nificant difference in our analysis (P = 0.55). The results of
multivariate analysis were similar with a study conducted
in FIGO stage IV patients [13].
Given the rarity of choriocarcinoma following term
pregnancy, we can not conduct a prospective study be-
cause the selection bias of our research is difficult to
avoid. However, this study, as the largest retrospective
cohort study to date, provides invaluable data that may
aid in better understanding this disease.
Conclusions
Postterm choriocarcinoma patients were usually accom-
panied by several high-risk factors that should received
combined chemotherapy to prevent delay in adequate
treatment. 5-fluorouracil-based multidrug chemother-
apy, which has been applied at PUMCH for several de-
cades, can be an effective initial treatment for postterm
choriocarcinoma patients. More emphasis should be
placed on those who have history of resistance to multi-
drug chemotherapy, liver metastasis or a FIGO score
greater than 12. The relationships between the prognosis
and multiple metastases or kidney metastasis require
additional study.
Table 4 The multivariate analysis of prognosis related factors on 272 postterm choriocarcinoma patients
Clinical and demographics characteristics Relative risk 95 % CI P value
Interval from index pregnancy >12 months 1.736 0.724–4.166 0.217
Metastatic sites ≥2 1.577 0.633–3.932 0.328
Resistance to multiagent chemotherapy 2.613 1.074–6.358 0.034
Liver metastasis 5.393 1.932–15.06 0.001
FIGO score >12 3.691 1.660–8.205 0.001
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Additional file
Additional file 1. The prognosis related factors of every patient were
listed in the worksheet. (XLSX 27.7 kb)
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